ReviewPituitary2022
Cardiovascular health and mortality in Cushing's disease.
Review in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Referral to Definitive Surgical Treatment in Cushing's Syndrome - An Odyssey That Requires Attention.Clinical endocrinology · 2026Article
- Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome.Endocrine reviews · 2026Review
- A Novel Evaluation of 24-hour Energy Metabolism in Cushing's Syndrome: The Metabolic Cost of Hypercortisolism.Journal of the Endocrine Society · 2026Article
- Cushing syndrome of different etiologies - cardiometabolic complications, venous thromboembolic events and mortality: data from ERCUSYN Krakow database.Frontiers in endocrinology · 2026Article
- Venous thromboembolism in Cushing syndrome: current evidence and a practical thromboprophylaxis algorithm.Frontiers in endocrinology · 2026Review
- Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.Diabetes care · 2025Observational
- Weight gain reversibility and BMI following treatment for Cushing's syndrome: long-term outcomes and potential predictors.Pituitary · 2025Article
- Neuroendocrine Breast Cancer-Associated Ectopic Adrenocorticotropic Hormone Syndrome Requiring Bilateral Adrenalectomy.Current oncology (Toronto, Ont.) · 2025Article
- The impact of hypercortisolism beyond metabolic syndrome on left ventricular performance: a myocardial work analysis.Cardiovascular diabetology · 2025Article
- Adrenal Volume Quantitative Visualization Tool by Multiple Parameters and an nnU-Net Deep Learning Automatic Segmentation Model.Journal of imaging informatics in medicine · 2025Article
- Impaired cardiac pumping function and increased afterload as determinants of early hemodynamic alterations in Cushing disease.Scientific reports · 2025Observational
- Serum Cortisol and Cardiovascular Disease Risk - A Potential Biomarker.Current cardiology reviews · 2025Review
- Allostatic load index in patients with pituitary tumours: a case control study.Frontiers in endocrinology · 2025Article
- Left ventricular subclinical systolic myocardial dysfunction assessed by speckle-tracking in patients with Cushing's syndrome.Endocrine · 2024Article
- Article
- Long-Term Glucocorticoid Exposure and Incident Cardiovascular Diseases-The Lifelines Cohort.The Journal of clinical endocrinology and metabolism · 2024Article
- Obesity-Related Hemodynamic Alterations in Patients with Cushing's Disease.Journal of clinical medicine · 2024Article
- Cardiac disease in Cushing's syndrome. Emphasis on the role of cardiovascular magnetic resonance imaging.Endocrine · 2024Review
- Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure to cortisol excess in Cushing's disease (CD) results in increased cardiovascular morbidity and reduces survival, with cardiovascular disease being a leading cause of death. At diagnosis, a significant number of patients have adverse cardiovascular profiles (e.g., obesity, diabetes or impaired glucose tolerance, dyslipidemia, hypertension, cardiac abnormalities and vascular disease). Remission of hypercortisolemia reduces but does not completely eliminate the cardiovascular complications; hazard ratios for myocardial infarction and stroke are high during long-term monitoring, highlighting the long-lasting effects of hypercortisolism and the importance of the timely diagnosis and successful management of this condition. Data on mortality of patients in remission are not consistent but in a multicenter study, an increased all-cause and circulatory mortality in patients with CD in remission for at least 10 years has been demonstrated. Cardiovascular morbidity requires particular focus and effective management during the care of patients with CD, from their presentation until long-term follow up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.